Dennis Carlo Net Worth

The estimated Net Worth of Dennis J Phd Carlo is at least $2.33 millió dollars as of 25 May 2022. Dennis Carlo owns over 250,000 units of Adamis Pharmaceuticals Corp stock worth over $412,618 and over the last 14 years he sold ADMP stock worth over $144,290. In addition, he makes $1,770,310 as President, Chief Executive Officer és Director at Adamis Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dennis Carlo ADMP stock SEC Form 4 insiders trading

Dennis has made over 13 trades of the Adamis Pharmaceuticals Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of ADMP stock worth $192,500 on 25 May 2022.

The largest trade he's ever made was exercising 250,000 units of Adamis Pharmaceuticals Corp stock on 25 May 2022 worth over $192,500. On average, Dennis trades about 18,187 units every 48 days since 2010. As of 25 May 2022 he still owns at least 535,867 units of Adamis Pharmaceuticals Corp stock.

You can see the complete history of Dennis Carlo stock trades at the bottom of the page.

Dennis Carlo biography

Dr. Dennis J. Carlo Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Carlo became President, Chief Executive Officer and a director of the Company in April 2009 in connection with the closing of the merger transaction between the Company and the corporation that now is a wholly-owned subsidiary of the Company, Adamis Corporation (“Old Adamis” ). Dr. Carlo was a co-founder of Old Adamis and served as its President and Chief Executive Officer, and a director, from October 2006 to April 2009. From 2003 to 2006, he served as president of Telos Pharmaceuticals, a private biotechnology company. From 1982 to 1987, he served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., a pharmaceutical and life science company which was acquired by Eli Lilly & Co in 1986. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberland, founded Immune Response Corporation, a public biotechnology company, where he served as its President and Chief Executive Officer from 1994 to 2002. Before then, he held various positions with life science companies, including Merck & Co. Dr. Carlo received a B.S. degree in microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University.

What is the salary of Dennis Carlo?

As the President, Chief Executive Officer és Director of Adamis Pharmaceuticals Corp, the total compensation of Dennis Carlo at Adamis Pharmaceuticals Corp is $1,770,310. There are no executives at Adamis Pharmaceuticals Corp getting paid more.

How old is Dennis Carlo?

Dennis Carlo is 76, he's been the President, Chief Executive Officer és Director of Adamis Pharmaceuticals Corp since 2009. There are 2 older and 10 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.

What's Dennis Carlo's mailing address?

Dennis's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300, SAN DIEGO, CA, 92130.

Insiders trading at Adamis Pharmaceuticals Corp

Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo és David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.

What does Adamis Pharmaceuticals Corp do?

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

Complete history of Dennis Carlo stock trades at Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corp executives and stock owners

Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Dennis Carlo,
  President, Chief Executive Officer, Director
• Ronald Moss,
  Chief Medical Officer
• Robert Hopkins,
  Chief Financial Officer, Senior Vice President - Finance
• Dr. Dennis J. Carlo,
  Pres, CEO & Director
• David Marguglio,
  Senior Vice President, Chief Business Officer and Director
• Karen Daniels,
  Vice President - Operations
• Richard Williams,
  Independent Chairman of the Board, Consultant
• David J. Marguglio,
  Sr. VP, Chief Bus. Officer & Director
• Mark Flather,
  Director, Investor Relations and Corporate Communications
• Roshawn Blunt,
  Independent Director, Consultant
• Howard Birndorf,
  Independent Director, Consultant
• Robert B. Rothermel,
  Consultant
• Eddie Wabern Glover,
  Chief Exec. Officer of US Compounding Inc
• Jennifer C. Suski,
  Sr. Director of Marketing
• Karen K. Daniels,
  VP of Operations
• David C. Benedicto,
  Chief Financial Officer
• Thomas Moll,
  Vice President of Research
• William C Denby,
  Director
• Eddie Wabern Glover,
  CEO of US Compounding, Inc.
• Robert B Rothermel,
  Director
• Ahmed Shayan Fazlur Eses Ho...,
  
• Tina Susan Nova,
  Director
• Kenneth M Cohen,
  Director
• Craig A Johnson,
  Director
• Meera J. Desai,
  Director
• David C. Benedicto,
  Chief Financial Officer
• Vickie S Reed,
  Director
• Ebrahim Versi,
  CEO
• Jannine Versi,
  Director